Melanoma | Topics

ctDNA Improved Predictor of Survival for Previously Treated Metastatic Uveal Melanoma
September 19, 2021

Previously treated patients with HLA-A*02:01-positive metastatic uveal melanoma saw survival prediction improvements with ctDNA when compared to RECIST 1.1.

Reduction In Disease Recurrence, Death With Adjuvant Pembrolizumab Noted in Resected High-Risk Stage II Melanoma
September 18, 2021

The use of adjuvant pembrolizumab resulted in a recurrence-free survival benefit for patients with resected high-risk stage II melanoma.

Addition of Relatlimab to Nivolumab Yields Longer TFI and Improved PFS2 in Metastatic or Unresectable Melanoma
September 18, 2021

Patients with previously untreated metastatic or unresectable melanoma achieved promising benefit following treatment with relatlimab/nivolumab combination therapy.